Treatment by combined chemotherapy for recurrent ovarian cancer.
نویسنده
چکیده
Neoplasms of the ovary are the cause of more deaths than any other female cancer. Approximately 23% of all gynaecological cancer are of ovarian origin, but 47% of all deaths from cancer of the female genital tract are due to ovarian carcinoma. Combination systemic chemotherapy frequently produces startling remissions and yet the overall five year survival rate remains 25%, the lowest survival statistic for any major pelvic malignancy. This report describes the recurrence of a tumour nine years after extensive surgery and radiotherapy and emphasises the importance of prolonged follow up as well as described treatment by combined chemotherapy after debulking of tumour (JPMA 35: 341 ,1985).
منابع مشابه
ترکیب جم سیتابین- کربوپلاتین در درمان عود سرطان تخمدان: یک مطالعه آیندهنگر
Normal 0 false false false EN-US X-NONE AR-SA MicrosoftInternetExplorer4 !mso]> st1":*{behavior:url(#ieooui) } /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal" mso-tst...
متن کاملSystematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer.
The aim of this systematic review is to critically evaluate cytoreductive surgery combined with heated intraoperative intraperitoneal chemotherapy in the treatment of ovarian cancer. A systematic review of all manuscripts published in the English literature that met predetermined inclusion criteria was carried out. Data concerning cytoreductive surgery, method and agents for administration of h...
متن کاملCommment on the review entitled “A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer” by Chiva LM and Gonzalez-Martin A.
•We raised some methodological concerns and made some comments on the systematic review by Chiva and colleague.•To state that Cytoreduction & HIPEC is not beneficial in front line and platinum sensitive recurrence is highly disputable.•Anyway, the combined treatment should be offered in the context of clinical trial; randomized data are urgently needed.
متن کاملCritical appraisal of bevacizumab in the treatment of ovarian cancer
Bevacizumab is the first molecular-targeted agent to be used for the treatment of ovarian cancer. Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor. Two randomized Phase III trials evaluated the combination of bevacizumab plus standard cytotoxic chemotherapy for first-line treatment of advanced ovarian cancer. Additional Phase III trials evaluated bevac...
متن کاملImproving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs.
One of the most significant developments in medical oncology practice has been the approval of various antiangiogenic drugs for the treatment of a number of different malignancies. These drugs include bevacizumab (Avastin), the anti-VEGF monoclonal antibody. Thus far, bevacizumab appears to induce clinical benefit in patients who have advanced metastatic disease only or primarily when it is com...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- JPMA. The Journal of the Pakistan Medical Association
دوره 35 11 شماره
صفحات -
تاریخ انتشار 1985